FUDANZHANGJIANG - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever as to the accuracy or completeness of the whole or any part of this announcement. assumes no liability for any loss arising from or arising from reliance on such content. Overseas regulatory announcement This announcement is made by Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (the "Company") under the Hong Kong Stock Exchange Ltd. Securities Listing Rules 13.10(B). This is to set forth the "Directors of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd." published by the company on the website of the Shanghai Stock Exchange. "Special Opinions of the Board of Directors on the Independence of Independent Directors" is for reference only. This document and its disclosures are based on It is compiled and published based on Chinese laws and regulations and relevant domestic regulatory requirements. By order of the board of directors Zhao Dajun Chairman As at the date of this announcement, the Board of Directors includes the following individuals: Mr. Zhao Dajun (Executive Director) Ms. Xue Yan (Executive Director) Mr. Shen Bo (Non-executive Director) Ms. Yu Xiaoyang (Non-executive Director) Mr. Wang Hongguang (Independent Non-executive Director) Mr. Lam Siu Wing (Independent Non-executive Director) Mr. Xu Peilong (Independent Non-executive Director) Ms. Qu Yanan (Employee Director) Shanghai, China March 30, 2026 *Identification only Board of Directors of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. Special opinions on the independence of independent directors According to the "Measures for the Administration of Independent Directors of Listed Companies" and the "Self-discipline of Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange" Regulatory Guidelines No. 1 - Standardized Operations, Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") independent directors Mr. Wang Hongguang, Mr. Lin Zhaorong and Mr. Xu Peilong are responsible for their own Conducted self-examination on independence and submitted the self-examination to the Board of Directors. The company's board of directors is independent of the company's current Evaluate the independence of the independent directors and issue the following special opinions: After verification, the service experience of Mr. Wang Hongguang, Mr. Lin Zhaorong, and Mr. Xu Peilong, the company’s independent directors, and The relevant self-examination documents signed confirm that each independent director does not hold any position in the company other than independent director. nor does he hold any position in the company's major shareholder company, and has no interest or interest in the company or its major shareholders. relationship or other relationships that may hinder his independent and objective judgment, and there is no influence on the independence of independent directors. situation, in compliance with laws and regulations such as the "Administrative Measures for Independent Directors of Listed Companies" and the provisions on independence in the "Articles of Association" Relevant requirements for the qualifications and independence of independent directors. Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. board of directors March 30, 2026